These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1762790)

  • 1. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma.
    Wang MB; Lichtenstein A; Mickel RA
    Otolaryngol Head Neck Surg; 1991 Oct; 105(4):517-27. PubMed ID: 1762790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer.
    Letessier EM; Sacchi M; Johnson JT; Herberman RB; Whiteside TL
    Cell Immunol; 1990 Oct; 130(2):446-58. PubMed ID: 2145080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
    Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
    Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
    Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
    Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First place--Resident Clinical Science Award 1990. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck.
    Strasnick B; Lagos N; Lichtenstein A; Mickel RA
    Otolaryngol Head Neck Surg; 1990 Oct; 103(4):537-49. PubMed ID: 2123311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors.
    Bailet JW; Lichtenstein A; Chen G; Mickel RA
    Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):855-62. PubMed ID: 9260552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
    van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
    Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological approach in the evaluation of regional lymph nodes of patients with squamous cell carcinoma of the head and neck.
    Verastegui E; Morales R; Barrera JL; Müeller A; Guzman B; Meneses A; Alfaro G
    Clin Immunol; 2002 Jan; 102(1):37-47. PubMed ID: 11781066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
    Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of in vitro biological functions in regional lymph node lymphocytes in squamous head and neck cancer.
    Saxon A; Portaro J
    Cancer Res; 1977 Apr; 37(4):1159-64. PubMed ID: 139203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.
    Mickel RA; Kessler DJ; Taylor JM; Lichtenstein A
    Cancer Res; 1988 Sep; 48(17):5017-22. PubMed ID: 3409231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and phenotypic analysis of lymphocytes in head and neck cancer.
    Snyderman CH; Heo DS; Johnson JT; D'Amico F; Barnes L; Whiteside TL
    Arch Otolaryngol Head Neck Surg; 1991 Aug; 117(8):899-905. PubMed ID: 1832546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation of the lymphokine-activated killer cell response in head and neck cancer patients by combination interleukin-2 and interferon-alpha.
    Wanebo H; Blackinton D; Weigel T; Turk P; Mehta S
    Am J Surg; 1991 Oct; 162(4):384-7. PubMed ID: 1951894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killing of autologous and allogeneic short-term cultured head and neck squamous carcinomas.
    Leess FR; Bredenkamp JK; Lichtenstein A; Mickel RA
    Laryngoscope; 1989 Dec; 99(12):1255-61. PubMed ID: 2601539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer.
    Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG
    Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induction of cytotoxic activity from regional lymph node lymphocytes in head and neck malignant tumor].
    Yoda J
    Nihon Jibiinkoka Gakkai Kaiho; 1992 May; 95(5):748-58. PubMed ID: 1619515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
    Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
    Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.
    Pak AS; Wright MA; Matthews JP; Collins SL; Petruzzelli GJ; Young MR
    Clin Cancer Res; 1995 Jan; 1(1):95-103. PubMed ID: 9815891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional immunosuppression in esophageal squamous cancer: evidence from functional studies with matched lymph nodes.
    O'Sullivan GC; Corbett AR; Shanahan F; Collins JK
    J Immunol; 1996 Nov; 157(10):4717-20. PubMed ID: 8906853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
    Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
    Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.